{"id":2042,"date":"2026-07-20T20:10:38","date_gmt":"2026-07-21T00:10:38","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2042"},"modified":"2026-07-20T20:25:00","modified_gmt":"2026-07-21T00:25:00","slug":"kolons-tg-c-misses-phase-3-endpoints","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2042","title":{"rendered":"Kolon’s TG-C Misses Phase 3 Endpoints"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Kolon TissueGene<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Trial Results (Phase 3 \u2014 Negative)<\/p>\n

Modality<\/strong><\/p>\n

Allogeneic Cell and Gene Therapy<\/p>\n

Asset<\/strong><\/p>\n

TG-C<\/p>\n

Target<\/strong><\/p>\n

TGF-β1 (Paracrine Modulation)<\/p>\n

Disease Area<\/strong><\/p>\n

Knee Osteoarthritis<\/p>\n

Summary<\/h4>\n

Kolon TissueGene’s allogeneic cell and gene therapy TG-C failed both co-primary endpoints in ACTiVION-II, a 531-patient U.S. Phase 3 study in knee osteoarthritis. Pain and WOMAC function improved substantially in both groups, but TG-C did not separate from saline placebo. A second independent Phase 3 readout is expected in October 2026, leaving the program’s regulatory path dependent on replication, subgroup analysis, and interpretation of an unexpectedly strong placebo response.<\/p>\n

What Happened<\/h4>\n

ACTiVION-II enrolled 531 people with Kellgren-Lawrence grade 2 or 3 knee osteoarthritis at 27 U.S. sites and randomized them 2:1 to a single intra-articular TG-C injection or saline placebo. At Month 12, the study failed to demonstrate statistically significant differences on either co-primary endpoint: visual-analog-scale pain and total WOMAC score.<\/p>\n

Reported mean VAS changes were approximately -38.7 points with TG-C and -39.2 with placebo, a between-group difference of 0.5 points and p-value of 0.8322. WOMAC changes were approximately -27.61 and -26.54, respectively, a difference of -1.07 points and p-value of 0.5701. The study also failed key secondary efficacy endpoints.<\/p>\n

TG-C was described as generally safe and well tolerated, with treatment-emergent adverse events reported in 83.9% of treated patients and 78.1% of placebo recipients. No new safety signal was identified. Total knee replacement occurred in 0.6% of treated patients and 5.3% of placebo recipients, an exploratory numerical difference that cannot overcome failure of the prespecified efficacy endpoints.<\/p>\n

Clinical Interpretation<\/h4>\n

The trial produced a clear statistical failure rather than a narrowly missed endpoint. Both arms improved substantially, but the treatment-placebo differences were minimal. The company’s explanation of an unexpectedly high placebo response is plausible in osteoarthritis studies involving pain, invasive procedures, and subjective outcome measures, yet a high placebo response is a known development risk that trial design must anticipate.<\/p>\n

Post hoc analyses may identify site effects, baseline imbalances, responder subsets, structural signals, or protocol-execution issues. Such findings can generate hypotheses but generally cannot replace failed prespecified endpoints. The October readout from ACTiVION-I is therefore pivotal. A positive, well-controlled replication could reopen regulatory discussion; a second failure would materially weaken the biological and development case.<\/p>\n

Mechanism and Evidence Burden<\/h4>\n

TG-C is a mixed allogeneic cell product combining chondrocytes with irradiated genetically modified cells engineered to express transforming growth factor beta 1. The intended effect is paracrine modulation of the joint environment following a single intra-articular injection. This approach seeks durable symptom improvement and potentially structural benefit without permanent engraftment of proliferating engineered cells.<\/p>\n

Osteoarthritis is biologically heterogeneous, and pain can be driven by cartilage loss, synovitis, subchondral bone, biomechanics, obesity, and central sensitization. A locally delivered biologic may be active in only a subset of patients, but successful development requires prospectively defining that population and selecting endpoints capable of demonstrating clinically meaningful benefit.<\/p>\n

Regulatory and Strategic Implications<\/h4>\n

The program already carries unusual regulatory history. Its Korean approval was revoked in 2019 after the identity of a cellular component differed from the originally described product, and the U.S. program experienced a clinical hold before resuming. Although long-term monitoring and the current study did not identify a new safety signal, prior product-characterization issues increase the importance of manufacturing consistency, cell identity, potency assays, and transparent regulatory documentation.<\/p>\n

The failure is relevant beyond Kolon because it illustrates the difficulty of developing regenerative and cell-based therapies for common musculoskeletal disease. A scalable off-the-shelf injection has significant theoretical advantages, but subjective endpoints, placebo effects, long follow-up, biological heterogeneity, and complex manufacturing create a high evidentiary and capital burden.<\/p>\n

Company and Product Background<\/h4>\n

Knee osteoarthritis is a chronic degenerative joint disease characterized by cartilage loss, changes in subchondral bone, inflammation, pain, stiffness, and declining physical function. Current treatment includes exercise, weight management, analgesics, intra-articular injections, and joint replacement. No widely accepted disease-modifying therapy reliably reverses established structural disease.<\/p>\n

Kolon TissueGene is developing TG-C as a single-injection allogeneic cell and gene therapy. The product mixes cartilage-derived cells with irradiated genetically modified cells that express TGF-β1, a signaling molecule involved in tissue regulation. The program is being evaluated in two independent U.S. Phase 3 trials under an FDA Special Protocol Assessment framework.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Pivotal outcome: both co-primary endpoints failed with minimal numerical separation from placebo.<\/li>\n
  • Study scale: 531 participants across 27 U.S. sites with 2:1 randomization.<\/li>\n
  • Safety: no new signal identified; adverse-event rates were broadly comparable.<\/li>\n
  • Next catalyst: independent ACTiVION-I Phase 3 topline results expected in October 2026.<\/li>\n
  • Principal risk: a second negative study could end the current U.S. registration strategy or require major redesign and additional trials.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a high-confidence negative clinical signal. The lack of separation on two co-primary endpoints, together with failure of key secondary endpoints, substantially weakens the current efficacy case. The lower numerical rate of knee replacement is interesting but exploratory and should not be elevated above the prespecified analysis.<\/p>\n

    The second Phase 3 trial now carries disproportionate importance. Even if it succeeds, regulators will need to reconcile discordant pivotal results and scrutinize site effects, endpoint behavior, product consistency, and the historical characterization issues. The program is not definitively terminated, but its path has become materially narrower and more complex.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 \u2014 High Negative. Importance:<\/strong> High as a negative signal \u2014 the trial was large, pivotal, and directly tested a late-stage cell and gene therapy in a common disease with substantial unmet need. Confidence:<\/strong> High for the endpoint failure, study design, and safety summary, since the results were publicly disclosed with detailed statistics; low for any subgroup rescue or future regulatory path until complete analyses and the second Phase 3 readout are available.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Kolon TissueGene’s allogeneic cell and gene therapy TG-C failed both co-primary endpoints in ACTiVION-II, a 531-patient U.S. Phase 3 study in knee osteoarthritis. Pain and WOMAC function improved substantially in both groups, but TG-C…<\/p>\n","protected":false},"author":1,"featured_media":2054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[149,150],"class_list":["post-2042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-kolon-tissuegene","tag-osteoarthritis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2042"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2042\/revisions"}],"predecessor-version":[{"id":2055,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2042\/revisions\/2055"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2054"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}